Tiltan's leading clinical-stage product, TL-118, is a combination of four drugs: A chemotherapeutic alkylating agent (metronomic administration i.e. low-dose-high-frequency) and 3 non-cytotoxic agents.
All four drugs are orally bioavailable, allowing the combination to be formulated as an oral dosage form. The TL-118 formulation was designed to maximize patients' convenience as the patients self-administer it orally, on a daily basis in the convenience of their home settings.
TL-118 is currently being evaluated in a metastatic pancreatic cancer study but can be applied to a broad spectrum of cancer indications due to its mode-of action. The trial is no longer recruiting patients.